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a b s t r a c t
INTRODUCTION: Although rare, gastrointestinal stromal tumors (GIST) are the most common mesenchy-
mal tumors affecting the gastrointestinal tract.
PRESENTATION OF CASE: Here we report the case of a 43-year-old man complaining of abdominal pain
along with a painless and palpable mass, which was conﬁrmed on magnetic resonance and multi-
slice computed tomography. Laparotomy revealed a nodular grayish-white ﬁrm noninﬁltrative mass
(39×27×14 cm, 6109g) that was well localized within the extramuscular and peritoneal surface of the
anterior wall of the stomach; complete tumor resection was performed. Histopathological examination
revealed features typical of GIST, including increased cellularity, increased mitotic activity, and spindle
shaped cells as well as positive immunoreactivity for KIT, CD34, and vimentin.
DISCUSSION: A review of literature revealed that GISTs of the size and weight similar to the present case
has been rarely reported. GIST most frequently involves the stomach. Although the etiopathogenesis
of this disease remains unclear, few well-documented familial cases have been associated with GIST
syndromes.
CONCLUSION: The primary treatment preferred is complete surgical excision of the tumor.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gastrointestinal stromal tumors (GISTs) are the most frequent
mesenchymal neoplasms of the gastrointestinal tract [1]. They are
rare, accounting for approximately 0.1–3% of all gastrointestinal
tumors [2]. Most GISTs occur in patients aged >50 years at the
time of diagnosis [3]. The etiological factors of GIST have not been
determined so far [4], with the stomach beingthe most frequently
(60%) affected site [5]. Clinically,mostpatientspresentwithasymp-
tomatic tumors are detected incidentally [6]. Generally, GISTs are
thought to originate from interstitial cells of Cajal or their pre-
cursors [3]. These tumors are usually positive for KIT (CD117),
and the combination of characteristic histopathological features
and KIT (CD117) positivity is observed in 95% of cases [2,7]. GISTs
have been associated with molecular alterations and mutations in
platelet-derived growth factor receptor alpha (PDGFRA) [7]. The
size of these tumors ranges from a few millimeters to several cen-
timeters in diameter [6]. GISTs >10 cm in diameter are referred
to as giant GISTs. To the best of our knowledge, giant GISTs of
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this size and weight have been rarely reported in the literature
(Table 1).
2. Presentation of case
A 43-year-old male arrived at the emergency department of
a state hospital with nonspeciﬁc systemic symptoms, abdom-
inal pain and weakness, and local examination was detected
to have a painless, palpable abdominal mass. Patient also gave
a no history of trauma or mass in the abdomen. Abdomi-
nal ultrasonography, computed tomography (CT), and magnetic
resonance (MR) imaging revealed the presence of a solid
cystic mass in the intra-abdominal region, which was clin-
ically considered as a tumor and was resected completely
(Fig. 1).
The tumor measured 39×27×14 cm in diameter and weighed
6109g. Serial sections of the surgical specimendidnot reveal tumor
inﬁltration to the any major organ compartment. Gross ﬁndings of
the nonperitonealized perimuscular or mesentery tissues included
the presence of a nodular, grayish-white, ﬁrm, well-localized and
well-demarcated, smooth mass. The cut surface of the tumor
revealed ill-deﬁned solid areas that were diffuse gray, with focally
hemorrhagic, myxoid, and cystic degeneration (Fig. 2). Macroscop-
ically, tumor perforation and ulceration were not observed and the
tumor margins were negative and focaly surgical margins close.
http://dx.doi.org/10.1016/j.ijscr.2015.04.037
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Anatomic location, age, gender, size (cm) and weight (kg) distributions of gastrointestinal stromal tumor
References Year Anatomic location Age (year) Gender Size (cm) Weight (kg)
Kitabayashi et al. [25] 2001 Stomach 75 M 15×11×4.4
Kimura et al. [26] 2004 Stomach** 84 F 20
Mehta et al. [22] 2005 Stomach 75 M 13×10
Dal Corso et al. [27] 2007 Stomach 88 F 17×13×9 1.630
Cruz Jr et al. [14] 2008 Stomach 37 M 32×25×21 3.750
Funahashi et al. [28] 2008 Stomach** 65 F 25×18×11
Alder et al. [29] 2013 Rectum 70 M 10×8.5
Cappellani et al. [30] 2013 Stomach 67 M 37×24×13 8.5
Colovic´ et al. [31] 2013 Stomach 52 F 20.5×16
Notani et al. [32] 2013 Stomach 58 M 22
Skandalos et al. [2] 2013 Stomacha 79 F 10.77×9.67
Misawa et al. [33] 2014 Jejunum 70 M 10×10
Mu et al. [34] 2014 Esophagus 29 M 13×12×5
Nakano et al. [35] 2014 Esophagus 65 F 18
Schneider et al. [36] 2014 Stomach 71 M 19×18×16 2.6
In our case This Stomachb 43 M 39×27×14 6.109
kg: kilogram, cm: centimetre, M: male, F: female.
a Lesser curvature.
b Extragastric growth.
Fig. 1. Computed tomography (CT) scan of the abdominal showed tumors fulﬁlling.
Histologically, the tumor appeared to consist predominantly
of spindle cells and multinucleated giant cells along with low-
moderate levels of cytological pleomorphism. The cells were
arranged in a prominent fascicular pattern with areas of col-
lagenization and mitosis [mitotic rate; 30 per 50 high-power
ﬁelds (HPF)]. In addition, focal necrosis and a myxoid stroma
were also present. The histopathological features of the lesion in
the present case were similar to those seen in high-risk tumors
(Fig. 3). Therefore, it was classiﬁed as a high-grade (grade 2) tumor.
Lymphovascular invasion and calciﬁcations were not observed.
However, the tumor cells were diffusely and strongly positive for
KIT (CD117, cytoplasmic and membranous), CD34 (Figs. 4 and 5)
and vimentin. The cells were focally positive for S-100 and neuron-
speciﬁc enolase, but negative for desmin, smooth muscle actin,
epithelialmembraneantigen, synaptophysin, calretinin, andCK5/6.
Fig. 2. Gross morphology: the macroscopicappearance of gastrointestinal stromal
tumors (GIST), multinodular features and gray-white ﬁrm, peritoneal surface intact.
Fig. 3. GIST low power view demonstrating prominent fasicular pattern, predomi-
nantly spindle cell cytomorphology (hematoxylin–eosin, originalmagniﬁcation×40
objective).
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Fig. 4. Immunohistochemical stain, CD117 (KIT), The tumor cells are diffuse and
strong positive(×40 objective).
Fig. 5. Immunohistochemical stain, CD34, diffuse and strong positive(×40 objec-
tive).
3. Discussion
Gastrointestinal stromal tumor is the terminology employed for
mesenchymal tumors of the gastrointestinal tract that are posi-
tive for the antigen KIT (CD117). GISTs originate from interstitial
cells of Cajal, which are known to originate from mesodermal pre-
cursors as opposed to those overlying the smooth muscle cells
[8]. A high percentage of GISTs is associated with PDGFRA gene
mutations,with several of them positively immunoreactive for KIT
(approximately 85% cases) [9]. By contrast, the KIT-negative GIST
is stomach or extragastrointestinal GIST that is positive PDGFRA
mutation [13]. The incidence of GIST is currently estimated at
about 4000 new cases per year in the United States [5]. The tumor
shows no sex predilection and usually occurs in adults [5], with a
mean reported age of 50.6 years [10]. GIST is extremely uncom-
mon in children and adolescents [11]. Some instances of GISTs
show a pattern of familial incidence suggestive of genetic pre-
disposition, whereas others are associated with neuroﬁbromatosis
and Carney’s triad [5]. The most common sites of occurrence are
the gastrointestinal tract of the stomach, and less frequently, the
small bowel, large bowel, and esophagus. These tumors, are also
known as extragastrointestinal GISTs (EGISTs), as they arise from
the omentum,mesentery, and retroperitoneum [10]. Gastrointesti-
nal bleeding, illness, anemia, and the presence of an abdominal
mass are the most common features of this disease [4]. Most
tumors arise as the submucosa or the muscularis propria growths
on the gastrointestinal wall, and some tumors arise from extra-
mural growths [5]. In the present case, the tumor presented as a
large protruding mass on the extramuscular and peritoneal surface
of the anterior wall of the stomach. The most signiﬁcant risk fac-
tors for GISTs are site (anatomical region), size, and mitotic rate
[4]. Orosz et al. have reported that tumor size can range from
0.5 to 30 cm, with a mean size of approximately 8.3 cm. Patients
with high-risk tumors present with tumors up to 8 cm in diam-
eter [12]. In the present study, the tumor was large enough to
almost completely occupy abdominal cavity. So far, to our knowl-
edge, no case with such a large tumor size and weight have been
previously reported in the literature. The histopathological pre-
sentation of GIST includes predominance of spindle cells, whereas
epithelioid cells are less commonly seen in some cases. In addi-
tion, other features, such as growth of cells in the form of fascicles,
palisade, and whorls, presence of skenoid ﬁbers, increased cellu-
larity, bizarre cell shapes, palisading, and myxoid matrix, may also
be present. [8]. Epithelioid type of stromal tumors occurs most
frequently in the stomach. As with other types of densely spin-
dle cells [5]. The criteria of GIST as recommended by the College
of American Pathologists for detecting high-risk cases of gastric
GISTs are as follows: mitotic rate; >5 per 50HPF, size; 5–10 cm, or
>10 cm [13]. Essentially, tumors >10 cm in diameter present the
risk of widespread metastasis [14]. The tumor described in the
present study was classiﬁed as a high-grade tumor (grade 2) with
a mitotic rate of >5/50HPF. Anatomical location in the stomach
acts as a favorable prognostic factor, and patientswith small-bowel
involvementusually experienceprogressive or higher risk behavior
[13]. Gastrointestinal stromal tumors metastasize most commonly
to the hepatic or peritoneal surfaces presenting as innumerable
metastatic nodules all over the abdominal cavity wall [4]. In the
present case, there were no metastases lymph node or liver. Most
GIST patients exhibit mutations in KIT exon 11 (70%), whereas KIT
exon 9 mutations are less common in GISTs (10–15%) [15]. The dif-
ferential diagnosis of GIST involves an immunohistochemical panel
composed of KIT, DOG1, S-100, desmin [4], smooth muscle actin,
and CD34 [16]. Espinosa et al. reported positive staining for DOG1,
CD117, and CD34 in 87%, 74%, and 59% cases of GIST, respectively
[17], whereas other studies have reported 100% and 89% positive
immunoreactivity for CD117 and CD34, respectively [18]. Recently,
Ríos-Moreno et al. evaluated 99 cases and concluded that immuno-
histochemically, GISTs often stain for CD117, DOG1, a total of 93.5%
positive [19]. The differential diagnosis of GIST includes benign
and malignant lesions consisting mostly of spindle cells, such as
retroperitoneal leiomyosarcomas. Retroperitoneal leiomyosarco-
mas are composed of cells that consistently express smoothmuscle
actin and desmin, but they are negative for CD34 and CD117 [20].
Greenson,in addition, benign inﬂammatory ﬁbroid polyps, ﬁbro-
matoses, schwannomas, and leiomyomas must also be included in
the differential diagnosis of GIST [21].
Mehta et al. Complete surgical excision is the treatment of
choice,and the projected 5-year survival rate of patients undergo-
ing surgical resection GISTs is 20–80% [22].
Quezada et al., on the other hand,more aggressive treatments
have been recommended for metastatic and unresectable tumors
[23], suchas, theuseof selective receptor tyrosinekinase inhibitors.
In the present study, we did not perform a biopsy in order to
reach a pathological diagnosis and, the patient did not receive
neoadjuvant (preoperative) therapy. Singer et al. [24] reported that
patients with spindle cell and epithelioid or mixed cell histology
had 5-year disease recurrence-free survival rates of 49%±7% and
23%±11%, respectively. Singer et al., the same study also demon-
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strated prognostic relations with KIT mutations where the disease
free survival rates in patients with exon 11 type mutations and
other mutation types was 89%±11% and 40%±8%, respectively
[24].
4. Conclusion
In conclusion, large sized, heavy tumors are rare in the case of
GISTs, which generally present with varying duration of symptoms
before surgery. These tumors may be difﬁcult to distinguish from
a number of other benign or malignant spindle cell lesions. Com-
plete surgical resection of the tumor along with adjuvant therapy
involving selective receptor tyrosine kinase inhibitors is effective,
and should be considered as primary modalities of treatment in
high-risk group GIST patients. Because the present case belongs
to the high-risk category, it is assumed to have a poor progno-
sis.
Conﬂict of interest
No ﬁnancial competing interests.
Ethical Approval
A copy of the written consent is available for review by the
Editor-in Chief of this journal upon request.
Consent
Written informed consent was obtained from the patient for
publication of this case report and its accompanying images.
Author contribution
AK conceived, designed and supervised the case report, and pro-
vided ﬁnal editing of the article. LG and AVK collected and analyzed
the data and drafted themanuscript. All authors read and approved
the ﬁnal manuscript.
References
[1] T. Osada, A. Nagahara, T. Kodani, A. Namihisa, M. Kawabe, T. Yoshizawa, T.
Ohkusa, S. Watanabe, Gastrointestinal stromal tumor of the stomach with a
giant abscess penetrating the gastric lumen, World J. Gastroenterol. 28 (2007)
2385–2387.
[2] I.K. Skandalos, N.F. Hotzoglou, K.Ch. Matsi, X.A. Pitta, A.I. Kamas, Giant extra
gastrointestinal stromal tumor of lesser omentum obscuring the diagnosis of
a choloperitoneum, Int. J. Surg. Case Rep. 4 (2013) 818–821, http://dx.doi.org/
10.1016/j.ijscr.2013.07.006 (Epub 20.07.13).
[3] M. Miettinen, J. Lasota, Gastrointestinal stromal tumors: pathology and
prognosis at different sites, Semin. Diagn. Pathol. 23 (2006)
70–83.
[4] B.P. Rubin, GIST, EGIST, Enzinger and Weiss’s Soft Tissue Tumors, 6th ed.,
Saunders, Philadelphia, PA, 2013, pp. 569–588.
[5] J.R. Goldblum, Gastrointestinal Stromal Tumors, in: R.D. Odze, J.R. Goldblum
(Eds.), Surgical Pathology of the GI Tract, Liver Biliary Tract, and Pancreas, 2nd
ed., Saunders, Philadelphia, PA, 2009, pp. 681–694.
[6] L. Zhou, C. Liu, J.G. Bai, J.C. Wei, K. Qu, F. Tian, M.H. Tai, R.T. Wang, F.D. Meng, A
rare giant gastrointestinal stromal tumor of the stomach traversing the upper
abdomen: a case report and literature review, World J. Surg. Oncol. 10 (2012)
66, http://dx.doi.org/10.1186/1477-7819-10-66
[7] E. Fülöp, S. Marcu, D. Milutin, A. Borda, Gastrointestinal stromal tumors:
review on morphology: diagnosis and management, Rom. J. Morphol.
Embryol. 50 (2009) 319–326.
[8] J. Rosai, Gastrointestinal Tract. Rosai and Ackerman’s Surgical Pathology, 10th
ed., Mosby Elsevier, New York, 2011, p. 585–816.
[9] B. Liegl-Atzwanger, J.A. Fletcher, C.D. Fletcher, Gastrointestinal stromal
tumors, Virchows Arch. 456 (2010) 111–127, http://dx.doi.org/10.1007/
s00428-010-0891-y (Epub 18.02.10).
[10] M. Vij, V. Agrawal, A. Kumar, R. Pandey, Cytomorphology of gastrointestinal
stromal tumors and extra-gastrointestinal stromal tumors: a comprehensive
morphologic study, J. Cytol. 30 (2013) 8–12, http://dx.doi.org/10.4103/0970-
9371.107505
[11] M. Benesch, Gastrointestinal Stromal Tumor, in: D. Schneider, I.B. Brecht, T.A.
Olson (Eds.), Andrea Ferrari Rare Tumors In Children and Adolescents,
Springer-Verlag, Berlin, 2012, pp. 279–280.
[12] Z. Orosz, T. Tornóczky, Z. Sápi, Gastrointestinal stromal tumors: a
clinicopathologic and immunohistochemical study of 136 cases, Pathol.
Oncol. Res. 11 (2005) 11–21 (Epub 31.03.05).
[13] Protocol for the Examination of Specimens From Patients With
Gastrointestinal Stromal Tumor (GIST) [Internet]. Washington: College of
American Pathologists (CAP); © 1996–2010 (updated 10.13; cited 11.11.14).
Available from: <http://www.cap.org/>.
[14] R.J. Cruz Jr., R. Vincenzi, B.M. Ketzer, A.L. Cecilio, L.A. Cepeda, Spontaneous
intratumoral bleeding and rupture of giant gastric stromal tumor (>30 cm) in
a young patient, World J. Surg. Oncol. 6 (2008) 76, http://dx.doi.org/10.1186/
1477-7819-6-76
[15] E.D. Tetzlaff, M.P. Davey, Optimizing adherence to adjuvant imatinib in
gastrointestinal stromal tumor, J. Adv. Pract. Oncol. 4 (2013)
238–250.
[16] R. González-Cámpora, M.D. Delgado, A.H. Amate, S.P. Gallardo, M.S. León, A.L.
Beltrán, Old and new immunohistochemical markers for the diagnosis of
gastrointestinal stromal tumors, Anal. Quant. Cytol. Histol. 33 (2011)
1–11.
[17] I. Espinosa, C.H. Lee, M.K. Kim, B.T. Rouse, S. Subramanian, K. Montgomery, S.
Varma, C.L. Corless, M.C. Heinrich, K.S. Smith, Z. Wang, B. Rubin, T.O. Nielsen,
R.S. Seitz, D.T. Ross, R.B. West, M.L. Cleary, M. van de Rijn, A novel monoclonal
antibody against DOG1 is a sensitive and speciﬁc marker for gastrointestinal
stromal tumors, Am. J. Surg. Pathol. 32 (2008) 210–218, http://dx.doi.org/10.
1097/PAS.0b013e3181238cec
[18] V.B. Shidham, M. Chivukula, D. Gupta, R.N. Rao, R. Komorowski,
Immunohistochemical comparison of gastrointestinal stromal tumor and
solitary ﬁbrous tumor, Arch. Pathol. Lab. Med. 126 (October (10)) (2002)
1189–1192.
[19] M.J. Ríos-Moreno, S. Jaramillo, S. Pereira Gallardo, A. Vallejo, M. Mora, A.
García-Escudero, J. Amérigo, R. González-Cámpora, Gastrointestinal stromal
tumors (GISTs): CD117, DOG-1 and PKC expression: is there any advantage
in using several markers? Pathol. Res. Pract. 15 (2012) 74–81, http://dx.doi.
org/10.1016/j.prp.2011.11.006 (Epub 24.12.11).
[20] M. Miettinen, J.M. Monihan, M. Sarlomo-Rikala, A.J. Kovatich, N.J. Carr, T.S.
Emory, L.H. Sobin, Gastrointestinal stromal tumors/smooth muscle tumors
(GISTs) primary in the omentum and mesentery: clinicopathologic and
immunohistochemical study of 26 cases, Am. J. Surg. Pathol. 23 (1999)
1109–1118.
[21] J.K. Greenson, Gastrointestinal stromal tumors and other mesenchymal
lesions of the gut, Mod. Pathol. 16 (April (4)) (2003) 366–375.
[22] R.M. Mehta, V.O. Sudheer, A.K. John, R.R. Nandakumar, P.S. Dhar, S.
Sudhindran, V. Balakrishnan, Spontaneous rupture of giant gastric stromal
tumor into gastric lumen, World J. Surg. Oncol. 3 (February (1)) (2005)
11.
[23] N. Quezada, F. Acevedo, A. Marambio, F. León, H. Galindo, J.C. Roa, N. Jarufe,
Complete pathological response to imatinib mesylate in an extraintestinal
gastrointestinal stromal tumor, Int. J. Surg. Case Rep. 5 (10) (2014) 681–685,
http://dx.doi.org/10.1016/j.ijscr.2014.05.009 (Epub 15.08.14).
[24] S. Singer, B.P. Rubin, M.L. Lux, C.J. Chen, G.D. Demetri, C.D. Fletcher, J.A.
Fletcher, Prognostic value of KIT mutation type, mitotic activity, and
histologic subtype in gastrointestinal stromal tumors, J. Clin. Oncol. 20
(September (8)) (2002) 3898–3905.
[25] K. Kitabayashi, T. Seki, K. Kishimoto, H. Saitoh, K. Ueno, I. Kita, S. Takashima, N.
Kurose, T. Nojima, A spontaneously ruptured gastric stromal tumor presenting
as generalized peritonitis: report of a case, Surg. Today 31 (4) (2001)
350–354.
[26] H. Kimura, T. Yoshida, S. Kinoshita, I. Takahashi, Pedunculated giant
gastrointestinal stromal tumor of the stomach showing extragastric growth:
report of a case, Surg. Today 34 (2) (2004) 159–162.
[27] H.M. Dal Corso, M. Solej, M. Nano, Giant gastrointestinal stromal tumor of the
stomach in an elderly patient, J. Gastrointest. Surg. 11 (June (6)) (2007)
804–806.
[28] H. Funahashi, Y. Okada, H. Sawai, T. Wakasugi, Y. Akamo, T. Manabe, Complete
extragastric growth in a giant gastrointestinal stromal tumor: report of a case,
Int. Surg. 93 (January–February (1)) (2008) 45–49.
[29] L.S. Alder, G. Elver, F.J. Foo, M. Dobson, Giant rectal gastrointestinal stromal
tumours: a diagnostic and therapeutic challenge, J. Surg. Case Rep. 2013
(December (12)) (2013), http://dx.doi.org/10.1093/jscr/rjt103, pii: rjt103.
[30] A. Cappellani, G. Piccolo, F. Cardì, A. Cavallaro, E. Lo Menzo, V. Cavallaro, A.
Zanghì, M. Di Vita, M. Berretta, Giant gastrointestinal stromal tumor (GIST) of
the stomach cause of high bowel obstruction: surgical management, World J.
Surg. Oncol. 11 (August) (2013) 172, http://dx.doi.org/10.1186/1477-7819-
11-172
[31] R. Colovic´, M. Micev, S. Matic´, N. Colovic´, N. Grubor, H.D. Atkinson, Malignant
stromal tumor of the stomach with giant cystic liver metastases prior to
treatment with imatinib mesylate, Vojnosanit Pregl. 70 (February (2)) (2013)
225–228.
[32] H. Notani, T. Kawamura, T. Sato, A. Hoshino, Y. Sato, A. Nakajima, A case of a
giant gastrointestinal stromal tumor of the stomach with extramural growth,
Gan To Kagaku Ryoho 40 (November (12)) (2013)
2179–2181.
[33] S. Misawa, M. Takeda, H. Sakamoto, Y. Kirii, H. Ota, H. Takagi, Spontaneous
rupture of a giant gastrointestinal stromal tumor of the jejunum: a case
CASE REPORT – OPEN ACCESS
94 A. Koyuncuer et al. / International Journal of Surgery Case Reports 12 (2015) 90–94
report and literature review, World J. Surg. Oncol. 12 (May) (2014) 153,
http://dx.doi.org/10.1186/1477-7819-12-153
[34] Z.M. Mu, Y.C. Xie, X.X. Peng, H. Zhang, G. Hui, H. Wu, J.X. Liu, B.K. Chen, D. Wu,
Y.W. Ye, Long-term survival after enucleation of a giant esophageal
gastrointestinal stromal tumor, World J. Gastroenterol. 20 (October (37))
(2014) 13632–13636, http://dx.doi.org/10.3748/wjg.v20.i37.13632
[35] A. Nakano, Y. Akutsu, K. Shuto, M. Uesato, T. Kono, I. Hoshino, N. Akanuma, T.
Maruyama, Y. Isozaki, H. Matsubara, Giant esophageal gastrointestinal
stromal tumor: report of a case, Surg. Today (June) (2014).
[36] C. Schneider, D.F. Hewin, Resection of giant gastric GIST with a new
generation ultrasonic scalpel device, World J. Clin. Cases 2 (January (1))
(2014) 9–11, http://dx.doi.org/10.12998/wjcc.v2.i1.9.
Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which
permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are
credited.
